In chat with Anil Singhvi, analyst Vikas Sethi picks Divis Lab, Sun Pharma as top buys; Know what works for the two
In todays edition of popular TV show Sadabahaar Sethi Saab, Market Analyst Vikas Sethi today recommended two stocks and both from the cash markets. Sethis recommendations were from the short term perspective. He told Zee Business Managing Editor Anil Singhvi that these two stocks are buys and both were from the pharma sector
In today's edition of popular TV show ‘Sadabahaar Sethi Saab’, Market Analyst Vikas Sethi today recommended two stocks and both from the Futures and Options markets. Sethi’s recommendations were from the short term perspective. He told Zee Business Managing Editor Anil Singhvi that these two stocks are buys and both were from the pharma sector. Know here which stocks are these and why this analyst picked them.
Top Stocks To Buy: Divi’s Lab
Analyst Vikas Sethi recommended Divi’s Lab today for bumper returns. This stock is currently trading around Rs 3140. He recommended buying in this stock at existing levels. The immediate term target price is Rs 3225 while the next near term price is Rs 3250. He puts the stop loss at Rs 3080.
Watch Zee Business Tweet Video Below:
Sethi has recommended this stock on a previous occasion too. This is India’s biggest company in API manufacturing, he said. The company will declare its Q2FY21 results on 7 September and it likely that the results will be strong in line with the results of other API manufacturers.
See Zee Business Live TV Streaming Below:
Top Stocks To Buy: Sun Pharma
Another stock picked by him was Sun Pharma. This is from the futures and options space. It is currently trading around Rs 467. He recommended buying around this level. The target price is Rs 485 in a very short term. He puts the stop loss at Rs 458.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.